Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Laroni

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Brain : a Journal of Neurology|October 21, 2017
Long-term disability progression in primary progressive multiple sclerosis: a 15-year studyMaria A Rocca, Maria Pia Sormani, Marco Rovaris, et al.
CNS Drugs|December 11, 2021
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational StudySerena Palmeri, Marta Ponzano, Federico Ivaldi, et al.
Journal of Autoimmunity|May 10, 2016
Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosisAlice Laroni, Eric Armentani, Nicole Kerlero de Rosbo, et al.
Patient Preference and Adherence|January 15, 2021
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient PerspectivesElisabeth G Celius, Heidi Thompson, Maija Pontaga, et al.
Genes and Immunity|June 12, 2025
Butyrate enhances CD56<sup>bright</sup> NK cell-driven killing of activated T cells and modulates NK cell chromatin accessibilityFederico Carlini, Margherita Squillario, Valentina Casella, et al.
BMC Neurology|June 3, 2014
Clinical baseline factors predict response to natalizumab: their usefulness in patient selectionAlice Laroni, Ilaria Gandoglia, Claudio Solaro, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 23, 2021
Predictors of Ocrelizumab Effectiveness in Patients with Multiple SclerosisMaria Cellerino, Giacomo Boffa, Caterina Lapucci, et al.
European Journal of Immunology|May 16, 2025
The Human Bone Marrow May Offer an IL-15-Dependent Survival Niche for EOMES<sup>+</sup> Tr1-Like CellsNadia Pulvirenti, Chiara Vasco, Camilla Righetti, et al.
Journal of the Neurological Sciences|September 15, 2019
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimodEmilio Vanoli, Nicola Montano, Giuseppe De Angelis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 6, 2020
Tailoring B cell depletion therapy in MS according to memory B cell monitoringGiovanni Novi, Francesca Bovis, Sabrina Fabbri, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Brain : a Journal of Neurology|October 21, 2017
Long-term disability progression in primary progressive multiple sclerosis: a 15-year studyMaria A Rocca, Maria Pia Sormani, Marco Rovaris, et al.
CNS Drugs|December 11, 2021
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational StudySerena Palmeri, Marta Ponzano, Federico Ivaldi, et al.
Journal of Autoimmunity|May 10, 2016
Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosisAlice Laroni, Eric Armentani, Nicole Kerlero de Rosbo, et al.
Patient Preference and Adherence|January 15, 2021
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient PerspectivesElisabeth G Celius, Heidi Thompson, Maija Pontaga, et al.
Genes and Immunity|June 12, 2025
Butyrate enhances CD56<sup>bright</sup> NK cell-driven killing of activated T cells and modulates NK cell chromatin accessibilityFederico Carlini, Margherita Squillario, Valentina Casella, et al.
BMC Neurology|June 3, 2014
Clinical baseline factors predict response to natalizumab: their usefulness in patient selectionAlice Laroni, Ilaria Gandoglia, Claudio Solaro, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 23, 2021
Predictors of Ocrelizumab Effectiveness in Patients with Multiple SclerosisMaria Cellerino, Giacomo Boffa, Caterina Lapucci, et al.
European Journal of Immunology|May 16, 2025
The Human Bone Marrow May Offer an IL-15-Dependent Survival Niche for EOMES<sup>+</sup> Tr1-Like CellsNadia Pulvirenti, Chiara Vasco, Camilla Righetti, et al.
Journal of the Neurological Sciences|September 15, 2019
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimodEmilio Vanoli, Nicola Montano, Giuseppe De Angelis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 6, 2020
Tailoring B cell depletion therapy in MS according to memory B cell monitoringGiovanni Novi, Francesca Bovis, Sabrina Fabbri, et al.
Pageof 8